Dr. Lal Pathlabs Ltd (NSE: LALPATHLAB) and Metropolis Healthcare Limited (NSE: METROPOLIS) are both listed in the Medical Diagnostic Centres industry. Dr. Lal Pathlabs has a market capitalisation of ₹31,567 Cr and Metropolis Healthcare ₹11,615 Cr, as of 9 Nov 2026. Their P/E ratios are 62.5 and 60.9 respectively. Return on equity is 21.48% for Dr. Lal Pathlabs and 13.37% for Metropolis Healthcare. Over one year, Dr. Lal Pathlabs's share price is up 24.2% and Metropolis Healthcare's is up 16.6%.
| Metric | Dr. Lal Pathlabs | Metropolis Healthcare |
|---|---|---|
| NSE Symbol | LALPATHLAB | METROPOLIS |
| BSE Code | 539524 | 542650 |
| Share Price | ₹2,020.60 | ₹584.50 |
| Market Cap | ₹31,567 Cr | ₹11,615 Cr |
| P/E Ratio | 62.5 | 60.9 |
| Return on Equity | 21.48% | 13.37% |
| Return on Assets | 13.34% | 8.36% |
| Dividend Yield | 1.06% | 0.36% |
| Beta (1Y) | 0.61 | 0.84 |
| 1-Year Price Change | +24.2% | +16.6% |
| 3-Month Price Change | +3.4% | +2.1% |
| 52-Week Range | ₹1,272.60 – ₹2,079.00 | ₹412.25 – ₹609.05 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹874 Cr | ₹497 Cr |
| Quarterly Net Profit | ₹194 Cr | ₹75 Cr |
| Net Margin | 22.2% | 15.2% |
| EPS (Basic, Quarter) | ₹11.51 | ₹3.64 |
| Results Basis | consolidated | consolidated |
| Headquarters | Gurugram, Haryana | Mumbai, Maharashtra |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers phlebotomist training programs. The company was founded in 1949 and is based in Gurugram, India.
Metropolis Healthcare Limited, together with its subsidiaries, provides pathology and related healthcare services in India, Africa, South Asia, the Middle East, and internationally. The company offers routine and semi-specialised pathology tests; advanced diagnostics, including genetic, molecular, and cytogenetic testing; preventive healthcare packages and corporate wellness screening; and clinical trial research, hospital lab management, and home collection services, as well as profiles, blood tests, and soft radiology services. It also provides diagnostic services for oncology, neurology, gy…
Dr. Lal Pathlabs has a market capitalisation of ₹31,567 Cr, against ₹11,615 Cr for Metropolis Healthcare as of 9 Nov 2026, about 2.7 times the size by market cap.
Dr. Lal Pathlabs has a P/E of 62.5 and Metropolis Healthcare a P/E of 60.9 as of 9 Nov 2026.
Dr. Lal Pathlabs has a return on equity of 21.48% and Metropolis Healthcare 13.37%.
Dr. Lal Pathlabs's share price is up 24.2% over one year and Metropolis Healthcare's is up 16.6%.
Dr. Lal Pathlabs reported revenue of ₹874 Cr and net profit of ₹194 Cr for Q2 FY27. Metropolis Healthcare reported revenue of ₹497 Cr and net profit of ₹75 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Health Care Providers and Services > Health Care Services > Medical Diagnostic Centres on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.